All In Biotech

BLA 761036 · Janssen Biotech

Darzalex

Daratumumab · Injection · CD38-directed Cytolytic Antibody

NovelBreakthrough therapyAccelerated approvalPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: May 28, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

Nov 16, 2015

Approved uses

15

Original approval plus efficacy supplements

Registered trials

426

89 Phase 3, 109 recruiting

FAERS reports

40,859

34,641 serious, 5,117 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 10, 2026.

DARZALEX is indicated for the treatment of adult patients with multiple myeloma: in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy. in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant. in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant. in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy. in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy. in combination with pomalidomide and dexamethasone in patients who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. as monotherapy, in patients who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent. DARZALEX is a CD38-directed cytolytic antibody indicated for the treatment of adult patients with multiple myeloma: in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant in combination with bortezomib, thalidomide,...

Mechanism: CD38 is a transmembrane glycoprotein (48 kDa) expressed on the surface of hematopoietic cells, including multiple myeloma and other cell types and tissues and has multiple functions, such as receptor mediated adhesion, signaling, and modulation of cyclase and hydrolase activity. Daratumumab is an IgG1κ human monoclonal antibody (mAb) that binds to CD38 and inhibits the growth of CD38 expressing tumor cells by inducing apoptosis directly through Fc mediated cross linking as well as by immune-mediated tumor cell lysis through complement dependent cytotoxicity (CDC), antibody dependent cell...

Therapeutic areas: Hematology and blood cancers

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 10, 2025 Supplement 54 · Efficacy OrphanLetterLabel
  • Jan 23, 2025 Supplement 51 · Efficacy OrphanLabelLetter
  • Jul 31, 2024 Supplement 50 · Efficacy OrphanLetterLabel
  • Jan 19, 2023 Supplement 44 · Efficacy OrphanLabelLetter
  • Mar 4, 2022 Supplement 41 · Efficacy OrphanLetterLabel
  • Aug 20, 2020 Supplement 29 · Efficacy OrphanLabelLetter
  • Jun 29, 2020 Supplement 26 · Efficacy OrphanLabelLetter
  • Sep 26, 2019 Supplement 24 · Efficacy · priority review OrphanLabelLetter
  • Jun 27, 2019 Supplement 20 · Efficacy · priority review OrphanLabelLetter
  • Feb 8, 2019 Supplement 16 · Efficacy OrphanLabelLetter
  • May 7, 2018 Supplement 13 · Efficacy · priority review OrphanLetterLabel
  • Jun 16, 2017 Supplement 5 · Efficacy OrphanLabelLetter
  • Nov 21, 2016 Supplement 4 · Efficacy · priority review Breakthrough therapyOrphanLabelLetter
  • Nov 21, 2016 Supplement 3 · Efficacy · priority review Breakthrough therapyOrphanLetterLabel
  • Nov 16, 2015 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalOrphanReviewLetterLabel
2 products under this application
  • DARZALEX · DARATUMUMAB 400MG/20ML · INJECTABLE, INJECTION · Prescription
  • DARZALEX · DARATUMUMAB 100MG/5ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Daratumumab" as an intervention, any sponsor and status, largest first.

All 426 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • plasma cell myeloma3,989
  • off label use3,646
  • infusion related reaction2,692
  • neutropenia2,082
  • pneumonia2,065
  • fatigue1,795
  • diarrhoea1,784
  • drug ineffective1,636
  • neuropathy peripheral1,500
  • death1,490
  • thrombocytopenia1,445
  • pyrexia1,348

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20145
201583
20161,385
20171,850
20182,874
20193,460
20203,566
20214,289
20225,045
20235,625
20245,286
20254,105
20263,286

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Darzalex (Daratumumab)

2024 spending

$18.0M

Beneficiaries

201

1,702 claims

Per beneficiary

$89,577

$139.46 per unit

View as table
YearSpending
2020$20,308,290
2021$14,704,062
2022$15,850,768
2023$16,069,467
2024$18,004,962

Part B: Darzalex (Daratumumab) · HCPCS J9145

2024 spending

$150M

Beneficiaries

2,246

19,505 claims

Per beneficiary

$66,731

2024 ASP limit $63.08 per unit

View as table
YearSpending
2020$837,409,111
2021$478,628,176
2022$318,319,113
2023$221,722,229
2024$149,876,829

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 323 on PubMed

Sponsor: Johnson & Johnson (Janssen)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.